Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
|Articles|August 9, 2022
Daily Medication Pearl: Sodium Polystyrene Sulfonate (Kayexalate)
Author(s)Saro Arakelians, PharmD
Kayexalate is a potassium binder indicated for the treatment of hyperkalemia.
Advertisement
Medication Pearl of the Day: Sodium Polystyrene Sulfonate (Kayexalate)
Indication: Kayexalate is a potassium binder indicated for the treatment of hyperkalemia.
Insight:
- Dosing: The average total daily adult oral dose of Kayexalate is 15 g to 60 g, administered as a 15-g dose (4 level teaspoons), 1 to 4 times daily.
- Dosage forms: Kayexalate is available as a cream to light brown, finely ground powder.
- Adverse events: Reported adverse reactions include anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, and vomiting.
- Mechanism of action: Kayexalate increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. The binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.
Source:
Advertisement
Related to this article
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5